While paclitaxel is a key anticancer drug for CS, as well as for epithelial ovarian cancer, several studies have demonstrated that SXR agonists such as rifampicin depress the activity of paclitaxel (6,7) and induce cellular proliferation in cancers such as ovarian (6), endometrial (8) and breast cancer (9). The gene discussed is NR1I2; the disease is ovarian carcinoma.